BioCentury’s translational roundup also highlights five papers on delivery advances

Over half the therapies have produced initial readouts, with results consistently pointing to clinical activity

Suzhou company gets $1.2B up front in deal with Japanese biopharma on three oncology products

BioCentury’s translational roundup also includes Roche’s PD-1 x IL-2 fusion, Charcot-Marie-Tooth investment, and three papers from start-ups

Plus: Promising data behind a new wave masked biologics promises 

An emerging wave of conditionally activated biologics is widening the therapeutic windows of validated tumor and checkpoint targets

The private equity firm’s life sciences unit backs start-up with rights to five programs

Next half will bring the first clinical efficacy data from Quell’s CAR Tregs; other companies are close behind

Also in BioCentury’s Clinical Report: Nektar, Cidara lead gainers on week’s data, and more

With Phase I/II efficacy in three cold tumor settings, Innovent’s IBI363 is advancing to registrational studies